항체 치료제 시장 : 형식, 투여 경로, 공급원, 질환 영역, 최종사용자별 - 세계 예측(2025-2030년)

The Antibody Therapeutics Market was valued at USD 248.79 billion in 2023, expected to reach USD 285.77 billion in 2024, and is projected to grow at a CAGR of 14.89%, to USD 657.50 billion by 2030.

Antibody therapeutics encompasses the use of monoclonal antibodies (mAbs) and other antibody formats to treat diseases, particularly cancers, autoimmune disorders, and infectious diseases. The necessity for these therapies is driven by their specificity, ability to target disease cells effectively, and reduced side effects compared to conventional treatments. They are applied in oncology, immunology, and virology, among others, with end-use extending to hospitals, research institutes, and specialty clinics. Market growth is primarily influenced by advancements in biotechnology, increasing incidence of chronic diseases, and substantial R&D investments. Moreover, regulatory approvals for novel antibody drugs and the integration of AI to enhance the drug discovery process are critical growth drivers. Emerging opportunities lie in the development of bispecific antibodies and antibody-drug conjugates, which offer enhanced efficacy and targeted action. Collaborations between biotech firms and research institutions are also paving the way for innovative therapeutic avenues. However, market limitations include high costs of treatment, complex manufacturing processes, and regulatory challenges, which could retard growth. There is also significant competition from alternative therapies such as small molecules and cell-based treatments. To capitalize on growth opportunities, firms should focus on optimizing supply chains and improving production efficiencies to lower costs. Additionally, patient-centric approaches, such as addressing unmet needs in rare diseases, could provide differentiation. Research should be directed towards shortening the development timeline and improving patient outcomes through personalized medicine. The market is characterized by rapid technological advancements and a competitive landscape, necessitating companies to stay agile and adaptive. Continuous innovation and strategic partnerships are essential for sustaining growth and maintaining market leadership in this dynamic and evolving field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibody Therapeutics Market

The Antibody Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of various cancers and infectious diseases
  • Increasing number of drug discovery activities worldwide
  • Government initiatives to promote access to antibody treatments and therapies
• Market Restraints
  • Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
• Market Opportunities
  • Advancements in the clinical development of antibody therapeutics
  • Ongoing approvals for novel antibody therapies and treatments
• Market Challenges
  • Insufficient efficacy and adverse effects associated with various treatments

Porter's Five Forces: A Strategic Tool for Navigating the Antibody Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibody Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibody Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibody Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibody Therapeutics Market

A detailed market share analysis in the Antibody Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibody Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibody Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include PharmAbcine Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, Incyte Corporation, Pfizer Inc., MoonLake Immunotherapeutics AG, AbbVie Inc., Almac Group Limited, Bayer AG, Novo Nordisk A/S, Genmab A/S, Astellas Pharma Inc., Aenova Holding GmbH, Argenx SE, Thermo Fisher Scientific Inc., Becton, Dickinson and Company, AbCellera Biologics Inc., GlaxoSmithKline PLC, Biogen Inc., Xencor, Inc., Pyxis Oncology, Inc., Emergent BioSolutions Inc., Antikor Biopharma, Evonik Industries AG, Sanofi S.A., Numab Therapeutics AG, Merus N.V., Adaptimmune Therapeutics PLC, Merck KGaA, Grifols, S.A., Baxter International Inc., Confo Therapeutics, Eli Lilly and Company, UCB S.A., Johnson & Johnson Services, Inc., GE HealthCare Technologies, Inc.,, BioNTech SE, TRIO Pharmaceuticals Inc., iTeos Therapeutics, Inc., Amgen Inc., MorphoSys AG, F. Hoffmann-La Roche Ltd., DotBio Pte. Ltd., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals, Inc., SAB Biotherapeutics, Inc., DH Life Sciences, LLC, ADC Therapeutics SA, and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Format, market is studied across Antibody Fragment, Bispecific Antibody, Monoclonal Antibody, and Polyclonal Antibody.
• Based on Route of Administration, market is studied across Intravenous and Subcutaneous.
• Based on Source, market is studied across Chimeric, Human, and Humanized.
• Based on Disease Areas, market is studied across Autoimmune & Inflammatory Diseases, Hematology, Immunology, Neurology, Oncology, and Osteology.
• Based on End User, market is studied across Hospitals and Long-term Care Facilities.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of various cancers and infectious diseases
    • 5.1.1.2. Increasing number of drug discovery activities worldwide
    • 5.1.1.3. Government initiatives to promote access to antibody treatments and therapies
  • 5.1.2. Restraints
    • 5.1.2.1. Incidences of product recalls of antibody therapeutics coupled with strict approval guidelines
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in the clinical development of antibody therapeutics
    • 5.1.3.2. Ongoing approvals for novel antibody therapies and treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Insufficient efficacy and adverse effects associated with various treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Format: Significant utilization of monoclonal antibodies due to numerous approvals by regulatory agencies for clinical use
  • 5.2.2. Route of Administration: Growing usage of intravenous administration of antibody therapeutics
  • 5.2.3. Source: Increasing use of human antibodies due to its biocompatible nature
  • 5.2.4. Disease Areas: Proliferating use of antibody therapeutics for infectious diseases
  • 5.2.5. End User: Evolving usage of antibody therapeutics in hospitals
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antibody Therapeutics Market, by Format

• 6.1. Introduction
• 6.2. Antibody Fragment
• 6.3. Bispecific Antibody
• 6.4. Monoclonal Antibody
• 6.5. Polyclonal Antibody

7. Antibody Therapeutics Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intravenous
• 7.3. Subcutaneous

8. Antibody Therapeutics Market, by Source

• 8.1. Introduction
• 8.2. Chimeric
• 8.3. Human
• 8.4. Humanized

9. Antibody Therapeutics Market, by Disease Areas

• 9.1. Introduction
• 9.2. Autoimmune & Inflammatory Diseases
• 9.3. Hematology
• 9.4. Immunology
• 9.5. Neurology
• 9.6. Oncology
• 9.7. Osteology

10. Antibody Therapeutics Market, by End User

• 10.1. Introduction
• 10.2. Hospitals
• 10.3. Long-term Care Facilities

11. Americas Antibody Therapeutics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Antibody Therapeutics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Antibody Therapeutics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
  • 14.3.2. AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies
  • 14.3.3. AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
  • 14.3.4. MBrace Therapeutics Raises USD 85 Million Series B Financing to Advance Oncology Pipeline of Innovative Antibody Drug Conjugate Candidates
  • 14.3.5. Salipro Partners with Icosagen to Develop Monoclonal Antibody Therapies
  • 14.3.6. AbCellera, Incyte Partner on Therapeutic Antibodies in Oncology
  • 14.3.7. Japan Grants Patent for Bioarctic's Parkinson's Disease Antibody
  • 14.3.8. U.S. FDA Approves TALVEY, a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
  • 14.3.9. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
  • 14.3.10. Crossbow Therapeutics Debuts with USD 80 Million in Series A Financing to Advance Antibody Therapeutics
  • 14.3.11. Pyxis Oncology to acquire Antibody Therapeutics Company Apexigen
  • 14.3.12. Merck to Develop mAb Through USD 10.8 Billion Acquisition
  • 14.3.13. Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology

Companies Mentioned

• 1. PharmAbcine Inc.
• 2. Takeda Pharmaceutical Company Limited
• 3. AstraZeneca PLC
• 4. Incyte Corporation
• 5. Pfizer Inc.
• 6. MoonLake Immunotherapeutics AG
• 7. AbbVie Inc.
• 8. Almac Group Limited
• 9. Bayer AG
• 10. Novo Nordisk A/S
• 11. Genmab A/S
• 12. Astellas Pharma Inc.
• 13. Aenova Holding GmbH
• 14. Argenx SE
• 15. Thermo Fisher Scientific Inc.
• 16. Becton, Dickinson and Company
• 17. AbCellera Biologics Inc.
• 18. GlaxoSmithKline PLC
• 19. Biogen Inc.
• 20. Xencor, Inc.
• 21. Pyxis Oncology, Inc.
• 22. Emergent BioSolutions Inc.
• 23. Antikor Biopharma
• 24. Evonik Industries AG
• 25. Sanofi S.A.
• 26. Numab Therapeutics AG
• 27. Merus N.V.
• 28. Adaptimmune Therapeutics PLC
• 29. Merck KGaA
• 30. Grifols, S.A.
• 31. Baxter International Inc.
• 32. Confo Therapeutics
• 33. Eli Lilly and Company
• 34. UCB S.A.
• 35. Johnson & Johnson Services, Inc.
• 36. GE HealthCare Technologies, Inc.,
• 37. BioNTech SE
• 38. TRIO Pharmaceuticals Inc.
• 39. iTeos Therapeutics, Inc.
• 40. Amgen Inc.
• 41. MorphoSys AG
• 42. F. Hoffmann-La Roche Ltd.
• 43. DotBio Pte. Ltd.
• 44. Bio-Rad Laboratories, Inc.
• 45. Bristol-Myers Squibb Company
• 46. Regeneron Pharmaceuticals, Inc.
• 47. SAB Biotherapeutics, Inc.
• 48. DH Life Sciences, LLC
• 49. ADC Therapeutics SA
• 50. Novartis AG